Published in Neurobiol Dis on October 17, 2011
GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol (2013) 1.20
Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci (2012) 1.17
Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives. Front Cell Neurosci (2014) 1.01
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast (2012) 1.00
Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synaptic plasticity, and visual functions in a mouse model of Down syndrome. Front Cell Neurosci (2011) 0.99
GluN2B antagonism affects interneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behavior. Neuropsychopharmacology (2013) 0.93
Dentate gyrus mediates cognitive function in the Ts65Dn/DnJ mouse model of Down syndrome. Hippocampus (2013) 0.86
Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. Neural Plast (2012) 0.83
Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome. Curr Opin Neurobiol (2012) 0.83
From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome. Neural Plast (2012) 0.82
Increased excitability and altered action potential waveform in cerebellar granule neurons of the Ts65Dn mouse model of Down syndrome. Brain Res (2012) 0.82
Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome. PLoS One (2014) 0.81
Size does not always matter: Ts65Dn Down syndrome mice show cerebellum-dependent motor learning deficits that cannot be rescued by postnatal SAG treatment. J Neurosci (2013) 0.81
New innovations: therapeutic opportunities for intellectual disabilities. Ann Neurol (2013) 0.80
Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics. Neural Plast (2012) 0.78
GABAergic dysfunction in pediatric neuro-developmental disorders. Front Cell Neurosci (2013) 0.78
Increased cortical synaptic activation of TrkB and downstream signaling markers in a mouse model of Down Syndrome. Neurobiol Dis (2015) 0.77
Altered Intrinsic Pyramidal Neuron Properties and Pathway-Specific Synaptic Dysfunction Underlie Aberrant Hippocampal Network Function in a Mouse Model of Tauopathy. J Neurosci (2016) 0.77
Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues. PLoS One (2015) 0.77
A 'cure' for Down syndrome: what do parents want? Clin Genet (2014) 0.75
The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome. Front Cell Neurosci (2017) 0.75
Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP. Front Behav Neurosci (2015) 0.75
Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis (2017) 0.75
Weaker control of the electrical properties of cerebellar granule cells by tonically active GABAA receptors in the Ts65Dn mouse model of Down's syndrome. Mol Brain (2013) 0.75
Altered intrinsic and network properties of neocortical neurons in the Ts65Dn mouse model of Down syndrome. Physiol Rep (2015) 0.75
Hippocampal Transcriptome Profile of Persistent Memory Rescue in a Mouse Model of THRA1 Mutation-Mediated Resistance to Thyroid Hormone. Sci Rep (2016) 0.75
Propofol differentially inhibits the release of glutamate, γ-aminobutyric acid and glycine in the spinal dorsal horn of rats. Iran J Basic Med Sci (2015) 0.75
Down's syndrome. Lancet (2003) 5.10
Short-term synaptic plasticity. Annu Rev Neurosci (1989) 5.10
Inactivity produces increases in neurotransmitter release and synapse size. Neuron (2001) 4.04
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci (2007) 3.74
G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron (1997) 3.52
Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron (2006) 3.51
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci (2004) 2.73
Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J Neurochem (1991) 2.66
Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A (1996) 2.32
Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res (1993) 2.29
G-protein mediated gating of inward-rectifier K+ channels. Eur J Biochem (2000) 2.17
GABA autoreceptors regulate the induction of LTP. Nature (1991) 2.13
Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat Neurosci (2010) 2.08
Coupling actin dynamics and membrane dynamics during endocytosis. Curr Opin Cell Biol (2002) 1.96
Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase. Proc Natl Acad Sci U S A (1993) 1.95
Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med (2009) 1.94
Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene (2003) 1.93
Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol (2004) 1.92
The Rac1 guanine nucleotide exchange factor Tiam1 mediates EphB receptor-dependent dendritic spine development. Proc Natl Acad Sci U S A (2007) 1.88
Regulation of gamma-aminobutyric acid synthesis in the brain. J Neurochem (1993) 1.86
Signalling via the G protein-activated K+ channels. Cell Signal (1997) 1.85
Subcellular localization of metabotropic GABA(B) receptor subunits GABA(B1a/b) and GABA(B2) in the rat hippocampus. J Neurosci (2003) 1.85
Molecular and cellular diversity of neuronal G-protein-gated potassium channels. J Neurosci (2005) 1.85
5-HT receptor regulation of neurotransmitter release. Pharmacol Rev (2007) 1.79
p145, a major Grb2-binding protein in brain, is co-localized with dynamin in nerve terminals where it undergoes activity-dependent dephosphorylation. J Biol Chem (1994) 1.75
Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology (1998) 1.63
Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol Genet (2007) 1.57
Characterization of synaptically elicited GABAB responses using patch-clamp recordings in rat hippocampal slices. J Physiol (1993) 1.56
The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci (2009) 1.46
Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett (2008) 1.38
Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J Comp Neurol (2007) 1.38
Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci Lett (2005) 1.36
GABA(B) receptors: synaptic functions and mechanisms of diversity. Curr Opin Neurobiol (2007) 1.34
Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J Comp Neurol (2009) 1.31
The physiological regulation of synaptic inhibition by GABAB autoreceptors in rat hippocampus. J Physiol (1993) 1.25
Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. J Neurophysiol (2006) 1.23
The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome. J Physiol (2006) 1.22
Synaptojanin 1 contributes to maintaining the stability of GABAergic transmission in primary cultures of cortical neurons. J Neurosci (2001) 1.19
Down syndrome cell adhesion molecule DSCAM mediates homophilic intercellular adhesion. Brain Res Mol Brain Res (2000) 1.19
Immunocytochemical localization of the alpha 1 and beta 2/3 subunits of the GABAA receptor in relation to specific GABAergic synapses in the dentate gyrus. Eur J Neurosci (1995) 1.16
The gamma 2 subunit of the GABAA receptor is concentrated in synaptic junctions containing the alpha 1 and beta 2/3 subunits in hippocampus, cerebellum and globus pallidus. Neuropharmacology (1996) 1.14
Over-inhibition: a model for developmental intellectual disability. Trends Neurosci (2007) 1.13
Upregulation of three Drosophila homologs of human chromosome 21 genes alters synaptic function: implications for Down syndrome. Proc Natl Acad Sci U S A (2009) 1.08
Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome (2011) 1.08
The power of comparative and developmental studies for mouse models of Down syndrome. Mamm Genome (2007) 1.07
Long-term memory in mental retardation: evidence for a specific impairment in subjects with Down's syndrome. Neuropsychologia (1997) 1.03
GABAB-GIRK2-mediated signaling in Down syndrome. Adv Pharmacol (2010) 0.95
Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes Brain Behav (2003) 0.95
Alu-splice cloning of human Intersectin (ITSN), a putative multivalent binding protein expressed in proliferating and differentiating neurons and overexpressed in Down syndrome. Eur J Hum Genet (1999) 0.95
Murine models for Down syndrome. Physiol Behav (2001) 0.93
Using mouse models to explore genotype-phenotype relationship in Down syndrome. Ment Retard Dev Disabil Res Rev (2007) 0.93
Down syndrome mouse models are looking up. Trends Mol Med (2006) 0.92
Attenuation of paired-pulse facilitation associated with synaptic potentiation mediated by postsynaptic mechanisms. J Neurophysiol (1997) 0.92
Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: a model of Down syndrome. J Comp Neurol (2006) 0.92
Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. J Neural Transm (Vienna) (2010) 0.90
Presynaptic lonotropic receptors. Handb Exp Pharmacol (2008) 0.87
Dyrk1A binds to multiple endocytic proteins required for formation of clathrin-coated vesicles. Biochemistry (2009) 0.86
Endogenous GABA activates small-conductance K+ channels underlying slow IPSCs in rat hippocampal neurons. J Neurophysiol (1997) 0.82
Upregulation of GABA neurotransmission suppresses hippocampal excitability and prevents long-term potentiation in transgenic superoxide dismutase-overexpressing mice. J Neurosci (1999) 0.81
Down syndrome and the trisomy 16 mouse: impact of gene imbalance on brain development and aging. Res Publ Assoc Res Nerv Ment Dis (1991) 0.79
Properties of isolated GABAB-mediated inhibitory postsynaptic currents in hippocampal pyramidal cells. Neuroscience (1994) 0.79
Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron (2006) 3.51
NGF signaling in sensory neurons: evidence that early endosomes carry NGF retrograde signals. Neuron (2003) 3.23
The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. Genet Med (2009) 2.83
One at a time, live tracking of NGF axonal transport using quantum dots. Proc Natl Acad Sci U S A (2007) 2.74
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci (2004) 2.73
Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron (2010) 2.20
Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment. Crit Rev Toxicol (2008) 1.93
Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol (2004) 1.92
Long-distance retrograde neurotrophic signaling. Curr Opin Neurobiol (2005) 1.84
Signaling endosome hypothesis: A cellular mechanism for long distance communication. J Neurobiol (2004) 1.63
Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction by modulating glutamate receptor recycling in Down's syndrome. Nat Med (2013) 1.61
Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J Comp Neurol (2009) 1.57
TrkB binds and tyrosine-phosphorylates Tiam1, leading to activation of Rac1 and induction of changes in cellular morphology. Proc Natl Acad Sci U S A (2006) 1.48
The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci (2009) 1.46
An AUPN/ANA survey of department leader opinions on the health of US academic neurology. Neurology (2004) 1.40
Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J Comp Neurol (2007) 1.38
The coming of age of axonal neurotrophin signaling endosomes. J Proteomics (2008) 1.35
Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res (2004) 1.32
Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J Comp Neurol (2009) 1.31
Comparative study of brain morphology in Mecp2 mutant mouse models of Rett syndrome. J Comp Neurol (2008) 1.26
Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell (2009) 1.25
Neuronal plasticity and dendritic spines: effect of environmental enrichment on intact and postischemic rat brain. J Cereb Blood Flow Metab (2002) 1.24
Endophilin B1 as a novel regulator of nerve growth factor/ TrkA trafficking and neurite outgrowth. J Neurosci (2008) 1.20
Membrane targeting by APPL1 and APPL2: dynamic scaffolds that oligomerize and bind phosphoinositides. Traffic (2007) 1.20
Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci (2009) 1.19
Evidence for both neuronal cell autonomous and nonautonomous effects of methyl-CpG-binding protein 2 in the cerebral cortex of female mice with Mecp2 mutation. Neurobiol Dis (2009) 1.18
Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci (2012) 1.17
A functional dynein-microtubule network is required for NGF signaling through the Rap1/MAPK pathway. Traffic (2007) 1.15
Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends Neurosci (2003) 1.12
IGFBP3 colocalizes with and regulates hypocretin (orexin). PLoS One (2009) 1.11
Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis (2011) 1.09
Somatosensory and sensorimotor consequences associated with the heterozygous disruption of the autism candidate gene, Gabrb3. Behav Brain Res (2010) 1.09
Cells in human postmortem brain tissue slices remain alive for several weeks in culture. FASEB J (2002) 1.07
Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Res (2010) 1.05
Illicium sesquiterpenes: divergent synthetic strategy and neurotrophic activity studies. Chemistry (2013) 1.04
Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation. Mol Neurodegener (2011) 1.02
Sleep/wake disruption in Alzheimer's disease: APOE status and longitudinal course. J Geriatr Psychiatry Neurol (2004) 1.01
The challenge of connecting the dots in the B.R.A.I.N. Neuron (2013) 0.99
Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. J Neurochem (2011) 0.99
Retrolinkin, a membrane protein, plays an important role in retrograde axonal transport. Proc Natl Acad Sci U S A (2007) 0.99
Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care. Neurosci Biobehav Rev (2013) 0.98
Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species. Biochemistry (2014) 0.98
Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12. Mamm Genome (2005) 0.96
Mouse models for Down syndrome-associated developmental cognitive disabilities. Dev Neurosci (2011) 0.95
Going the distance, or not, with neurotrophin signals. Cell (2004) 0.95
Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome. J Comp Neurol (2011) 0.94
Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging (2013) 0.94
A novel method for producing mono-biotinylated, biologically active neurotrophic factors: an essential reagent for single molecule study of axonal transport. J Neurosci Methods (2011) 0.94
Using mouse models to explore genotype-phenotype relationship in Down syndrome. Ment Retard Dev Disabil Res Rev (2007) 0.93
Trafficking the NGF signal: implications for normal and degenerating neurons. Prog Brain Res (2004) 0.92
Enantioselective synthesis of (-)-jiadifenin, a potent neurotrophic modulator. Org Lett (2011) 0.92
Deficiencies in the region syntenic to human 21q22.3 cause cognitive deficits in mice. Mamm Genome (2010) 0.91
Sleep and EEG features in genetic models of Down syndrome. Neurobiol Dis (2007) 0.90
Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J Clin Invest (2016) 0.87
Neurobiological elements of cognitive dysfunction in down syndrome: exploring the role of APP. Biol Psychiatry (2011) 0.85
AxonQuant: A Microfluidic Chamber Culture-Coupled Algorithm That Allows High-Throughput Quantification of Axonal Damage. Neurosignals (2014) 0.84
Imaging the Alzheimer brain. J Alzheimers Dis (2011) 0.83
Calcium tips the balance: a microtubule plus end to lattice binding switch operates in the carboxyl terminus of BPAG1n4. EMBO Rep (2012) 0.83
Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits. Hum Mol Genet (2013) 0.83
Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome. Curr Opin Neurobiol (2012) 0.83
Potential use of γ-secretase modulators in the treatment of Alzheimer disease. Arch Neurol (2012) 0.83
Genetic analysis of Down syndrome facilitated by mouse chromosome engineering. Bioeng Bugs (2012) 0.80
Aging and intellectual disability: insights from mouse models of Down syndrome. Dev Disabil Res Rev (2013) 0.79
Immobilizing reporters for molecular imaging of the extracellular microenvironment in living animals. ACS Chem Biol (2011) 0.79
Nemitin, a novel Map8/Map1s interacting protein with Wd40 repeats. PLoS One (2012) 0.77
A SxIP motif interaction at the microtubule plus end is important for processive retrograde axonal transport. Cell Mol Life Sci (2014) 0.76
Editorial: The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective. Curr Alzheimer Res (2016) 0.76
Hippocampal network alterations in Alzheimer's disease and Down syndrome: from structure to therapy. J Alzheimers Dis (2011) 0.76
Real-time imaging of Rab5 activity using a prequenched biosensor. ACS Chem Biol (2011) 0.75